Australian Group on Antimicrobial Resistance
The Australian Group on Antimicrobial Resistance (AGAR) is a collaboration of clinicians and scientists from key microbiology laboratories around Australia that conduct targeted surveillance of selected pathogens and collect demographic, treatment and outcome data, and data on antimicrobial resistance rates. AGAR is an important core component of the Antimicrobial Use and Resistance Surveillance System (AURA).
The Australian Society for Antimicrobials coordinates AGAR to collect, analyse and report on the data submitted by participating laboratories.
Laboratories participate in the AGAR surveys by providing laboratory data and isolates to the AGAR coordinating laboratories. These AGAR laboratories collate the data, undertake molecular testing on isolates and prepare reports for the following three programs:
- Gram-negative Sepsis Outcome Program (GNSOP)
- Staphylococcus aureus Sepsis Outcome Program (ASSOP)
- Australian Enterococcus Sepsis Outcome Program (AESOP)
AGAR publishes annual reports on the outcomes of these surveys, as well as a range of articles and presentations on findings on its website. The 2020 AGAR Sepsis Outcome Programs Report is now available below.
AGAR Sepsis Outcome Programs reports
AGAR collaborates with the Commission to prepare reports for AURA that bring together the key findings of the three sepsis outcome programs, as a means of increasing access to antimicrobial resistance surveillance data to inform response strategies and improve the safety of care provided to patients.
AGAR Sepsis Outcome Programs fact sheets
AGAR technical papers
The Commission and AGAR have collaborated on detailed analyses of data relating to methicillin-resistant Staphylococcus aureus (MRSA) bacteramias, including changes in the clones that cause MRSA disease.